Study details
Enrolling now
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
LB Pharmaceuticals Inc.
NCT IDNCT07363577ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Ages
18–65
Locations
1 site in CA
About this study
This Phase 3 study is focused on people with schizophrenia. The primary outcome being measured is Change from baseline to Week 6 on the Positive and Negative Syndrome Scale.
Based on ClinicalTrials.gov records.
PhasePhase 3
Routeoral
Primary goalChange from baseline to Week 6 on the Positive and Negative Syndrome Scale
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low11%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug routes
oral
Endpoints
Primary: Change from baseline to Week 6 on the Positive and Negative Syndrome Scale
Secondary: Evaluate the Safety and Tolerability of LB-102
Body systems
Psychiatry / Mental Health